Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib

Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib

<p>Abstract</p> <p>Background</p> <p>Tyrosine kinase inhibitors (TKIs) are currently approved for the treatment of metastatic renal cell carcinoma (mRCC). The cardiotoxic effects of sorafenib and sunitinib may cause hypertension, left ventricular ejection fraction (LVEF...

Full description

Bibliographic Details
Main Authors: Pantaleo Maria, Mandrioli Anna, Saponara Maristella, Nannini Margherita, Erente Giovanna, Lolli Cristian, Biasco Guido
Format: Article
Language:English
Published: BMC 2012-06-01
Series:BMC Cancer
Subjects:
Sorafenib
renal cell carcinoma
coronary syndrome
cardiotoxicity
cardiac ischemia/infarction
Online Access:http://www.biomedcentral.com/1471-2407/12/231

Internet

http://www.biomedcentral.com/1471-2407/12/231

Similar Items